首届创新药上市解决方案大赛召开！可T+0交易的港股创新药ETF(159567)跟踪指数涨超4%，实时换手率突破68%排名同指数第一

Group 1 - The Hong Kong stock market showed strong performance on June 4, with the innovative drug sector leading the market gains, particularly stocks like Innovent Biologics and Zai Lab rising over 12% [1] - The Hong Kong innovative drug ETF (159567) recorded a trading volume exceeding 1.1 billion yuan for the fourth consecutive trading day, indicating high market enthusiasm [1] - The "First Innovative Drug Listing Solution Competition" held in Guangzhou focused on revolutionary new drugs, aiming to address the gap in China's innovative drug development and clinical application [1] Group 2 - The Hong Kong innovative drug index's price-to-earnings ratio decreased from 64 times on February 21 to 29 times on June 4, highlighting a significant reduction in valuation and improved cost-effectiveness for investors [1] - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from advancements in AI, the international expansion of domestic innovative drugs, and the introduction of new insurance policies [2] - The domestic innovative drug sector has shown strong investment value due to continuous technological breakthroughs and enhanced global competitiveness, with upcoming ASCO conference showcasing Chinese companies' achievements in oncology [2]